NCT06559007View on ClinicalTrials.gov

Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

January 6, 2025

Study Completion Date

March 3, 2025

Conditions
Prostate Cancer
Interventions
DRUG

HRS-5041 dose level 1

Single dose of HRS-5041 orally administered

DRUG

HRS-5041 dose level 2

Single dose of HRS-5041 orally administered

Trial Locations (1)

3004

Nucleus Network Melbourne, Melbourne

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY

NCT06559007 - Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants | Biotech Hunter | Biotech Hunter